Business Wire

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Share

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. Nuwiq® is a 4th generation human cell line-derived recombinant FVIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients of all ages with haemophilia A. The symposium, entitled ‘Going further to meet clinical needs: New data with Nuwiq ® ▼ (simoctocog alfa; human-cl rFVIII) from clinical trials and real-world experience’, focused on the challenges within the current haemophilia treatment landscape and opportunities to improve patient care.

The symposium, chaired by Craig Kessler, addressed the reality that no two haemophilia A patients are the same. An optimal treatment approach should therefore reflect each individual patient’s profile. Striving towards this goal, two approaches to using pharmacokinetic (PK) data to personalise prophylaxis with Nuwiq® were presented in the symposium. John Pasi (The Royal London Hospital, London, UK) shared a summary of the NuPreviq study, which uses an individual’s PK profile to optimise the treatment plan1. This individualised dosing approach enabled over half (57%) of patients in the NuPreviq study to reduce dosing with Nuwiq® to twice weekly or less, whilst maintaining effective bleed protection (median annualised bleeding rate [interquartile range]: 0 [0, 1.9]) for all bleeds). During personalised prophylaxis with Nuwiq®, 83% of patients were spontaneous bleed free. A second approach, using WAPPS (Web Accessible Population Pharmacokinetics Program), was presented by Stacy Croteau (Boston Children’s Hospital, Boston, USA). This approach uses the PK analysis of a group of people to predict the optimal treatment for an individual, and provides a flexible approach to dosing that requires fewer samples. A Nuwiq®-specific WAPPS model is available and is based on PK data from 114 patients, including 26 children, treated with Nuwiq®. These approaches represent promising steps towards achieving personalised haemophilia care.

For previously untreated patients (PUPs), the risk of inhibitor development remains the greatest concern with haemophilia treatment. Ellis Neufeld (St. Jude Children’s Research Hospital, Memphis, USA) presented an overview of interim data from the NuProtect study, which is investigating Nuwiq® in PUPs2. The interim data indicate a cumulative incidence of high-titre inhibitors of only 12.8% in patients treated with Nuwiq®.The presentation also included data from a recent sub-analysis of inhibitor development based on patients’ F8 gene mutation status3. This analysis demonstrated a cumulative inhibitor incidence of 26.7% in patients with high-risk mutations, whilst no patients with low-risk mutations developed inhibitors. Dan Hart (The Royal London Hospital, London, UK) presented a novel genomic approach to further analyse data from the NuProtect study, with the aim of predicting inhibitor risk using transcriptional profiles.

Ri Liesner (Great Ormond Hospital for Children, London, UK) presented real-world data on the use of Nuwiq® for immune tolerance induction (ITI), which remains the only proven strategy to eradicate inhibitors. Three of the five patients in the cohort have achieved eradication of inhibitors, while the other two remain on ITI and show continued decline in inhibitor levels.

Larisa Belyanskaya, Head of Octapharma’s IBU Haematology stated “we at Octapharma are delighted with the excellent data presented at WFH 2018, which build on the growing wealth of positive experience with Nuwiq ® . The broad range of data demonstrate the expanding value of Nuwiq ® in clinical practice and highlight Octapharma’s commitment to ‘going further’ to address the developing demands of haemophilia A patients”. Olaf Walter, Board Member at Octapharma, added “The data presented at the symposium build on a broad portfolio of clinical experience with Nuwiq ® . The WFH congress is a key platform for sharing information in the haemophilia field and Octapharma is proud to present new data on Nuwiq to the international haemophilia community at this meeting”.

About Nuwiq ®

Nuwiq® is a 4th generation rFVIII protein4, produced in a human cell line without chemical modification or fusion with any other protein5. Nuwiq® is cultured without additives of human or animal origin5, is devoid of antigenic non-human protein epitopes6 and a high affinity for the von Willebrand coagulation factor7. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs8,9 (190 individuals) with severe haemophilia A, including 59 children10. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.

About Haemophilia A

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.

About Octapharma

The vision of Octapharma is “Our passion drives us to provide new health solutions advancing human life”. Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood. Our company values are Ownership, Integrity, Leadership, Sustainability and Entrepreneurship.

In 2017, the Group achieved €1.72 billion in revenue, an operating income of €349 million and invested €287 million to ensure future prosperity. Octapharma employs around 7,700 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:

• Haematology (coagulation disorders)

• Immunotherapy (immune disorders)

• Critical care

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

References:

1. Lissitchkov T, et al. Haemophilia 2017;23:697-704.

2. Liesner R, et al. Haemophilia 2018;24:211-220.

3. Liesner R, et al. Blood eLetter 2018; available at http://www.bloodjournal.org/content/early/2017/08/02/blood-2017-06-791756

4. Lieuw K. J Blood Med 2017; 8: 67–73.

5. Casademunt E, et al. Eur J Haematol 2012; 89: 165-76.

6. Kannicht C, et al. Thromb Res. 2013; 131: 78-88.

7. Sandberg H, et al. Thromb Res 2012; 130: 808-17.

8. Valentino LA, et al. Haemophilia 2014; 20(Suppl. 1): 1-9.

9. Lissitchkov T, et al. Haemophilia 2017; 23: 697–704.

10. Klukowska A, et al. Haemophilia 2016; 22, 232-39.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com
or
Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PAN Finance Names Libertex ‘Global CFD Broker of the Year’29.3.2024 08:25:00 EET | Press release

As the first quarter of 2024 draws to a close, Libertex is thrilled to announce its first accolade of the new year! The established global financial publication PAN Finance has determined Libertex to be the ‘CFD Broker of the Year – Global 2024’ following a rigorous evaluation process conducted by the publication's highly experienced editorial and research teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328235325/en/ (Graphic: Libertex) PAN Finance is a trusted source of global financial intelligence with an impressively wide readership across 150 countries. Its ecosystem includes a quarterly magazine, special reports, a news website, and various social media channels. As an organisation, PAN Finance is committed to providing concise, intelligent, and up-to-date news for a worldwide readership of specialists spanning the entire finance industry. The company's awards programme aims to serve as a true indicator of exc

Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.29.3.2024 04:39:00 EET | Press release

Midea Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328526418/en/ Background: Midea Group, a leading global technology group, recently released its 2023 Environmental, Social, and Governance (ESG) Report with ambitious sustainable development goals set for 2030. They include achieving over 500 megawatts of photovoltaic power generation, reducing greenhouse gas emission intensity (scopes 1 and 2) by 0.040, secure Energy Management System Certification for 50 factories, and achieve 100% carbon footprint accounting for major categories of smart home appliances. This is aligned with the Sustainable Development Report Standards of the Global Report Standards of the Global Reporting Initiative (GRI). The new report and campaign focuses on four dimensions: Protect the Blue Planet, Build a Harmonious Community, Practice 'Bring Great Innovations to Life', and Jointly Create the Prosperous Ecology. The campaign: Midea’s ESG

DC Secretary Announces Annual Determinations Committees Outcome28.3.2024 23:14:00 EET | Press release

DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 27, 2024. Voting Dealers (for all regions): Voting Non-Dealers (for all regions): Bank of America N.A. Citadel LLC Barclays Bank plc Elliott Management Corporation BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Voting Dealer for the Americas, EMEA, AEJ, and Japan Determination Committees: Mizuho Securities Co., Ltd. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/. View source version on businesswire.com: https://www.businesswire.com/news/home/20240328441002/en/ Contact information Press Inquiries: Orlando Figueroa orlando.figueroa@citadelspv.com

Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management28.3.2024 19:02:00 EET | Press release

HTEC, a global digital consulting, software engineering, and product development company, is announcing a strategic collaboration with G2 Risk Solutions (G2RS), the preeminent provider of end-to-end bankruptcy technology solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328622816/en/ HTEC & G2 Risk Solutions Partnership (Photo: Business Wire) Under the agreement, G2RS will engage HTEC to incorporate its leading-edge technology into G2RS’ premier bankruptcy management platform. As the creators of the most comprehensive national bankruptcy database and the first bankruptcy management portal, G2RS is an industry pioneer. By adding HTEC’s premium engineering to the G2RS technology stack, G2RS will offer new and innovative functionalities to help clients expedite financial recoveries, increase data protection, and reduce operational inefficiencies in the bankruptcy management life cycle. “We are thrilled to be a part o

LambdaTest Launches The Phoenix Project, an Employee Resource Group for Women28.3.2024 18:00:00 EET | Press release

LambdaTest, a leading cloud-based unified testing platform, announced the launch of The Phoenix Project, an Employee Resource Group (ERG) dedicated to supporting and promoting the success of its female employees. “LambdaTest is committed to fostering a diverse, inclusive, and equitable workplace where all employees feel valued and empowered to reach their full potential,” said Chandini Chopra, VP of People and Culture at LambdaTest. “The Phoenix Project is a critical step towards achieving this goal by providing a platform for professional development, networking, and mentorship, especially for our women employees.” The Phoenix Project Aims To: Offer professional development workshops, networking opportunities, and dedicated time off for women to participate in ERG initiatives. Provide mentorship programs connecting senior female employees with mentees. Promote leadership development among women within the company. Create a sense of community for women in the workplace. Leadership and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye